Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00237263 | An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States | PHASE2 | COMPLETED | 285 | — | — | Feb 1, 2003 | Jul 1, 2007 | Jan 11, 2024 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Entacapone | DRUG | - |
Inclusion Criteria: * Attended the Phase IIb study * Able to fill out the patient diary Exclusion Criteria: * Serious heart, pulmonary, renal, hepatic or gastrointestinal disease * Dementia symptoms * Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may a...